XNAS · Healthcare · Biotechnology
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-02-26 | H1 2026 | -0.20 | -0.03 | +84.50% | $51.3M | ✅ Beat | -4.55% | -7.33% | -15.13% |
| 2025-02-26 | H1 2025 | — | -4.20 | — | $3.2M | — | -1.15% | -5.73% | -22.96% |
| 2024-08-28 |
| FY 2024 |
| — |
| -8.91 |
| — |
| $5.9M |
| — |
| +1.57% |
| +2.83% |
| +19.31% |
| 2023-08-30 | Q4 2023 | -0.30 | -0.28 | +6.67% | $2.1M | ✅ Beat | +12.59% | +4.90% | -13.99% |
| 2023-05-25 | Q3 2023 | -0.34 | -0.25 | +25.29% | $1.9M | ✅ Beat | +5.22% | +2.03% | +11.30% |
| 2023-02-27 | Q2 2023 | -0.28 | -1.32 | -371.43% | $2.1M | ❌ Miss | +3.13% | +0.63% | -1.56% |
Showing last 6 quarters.